Findings

What do systematic reviews say?

8 questions · 9 findings · 3 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 33.3%Low 1 · 11.1%Moderate 4 · 44.4%High 1 · 11.1%

Fondaparinux vs placebo

Major bleeding · people with ST of the leg

Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.86]
1 study · 2987 participants
Moderate

Fondaparinux vs low molecular weight heparin

Major bleeding · people requiring prevention of venous thromboembolism

Fondaparinux leads to higher major bleeding compared with LMWH (high certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 1.38 [1.09, 1.75]
11 studies · 12501 participants
High

Fondaparinux vs variable dose warfarin

Major bleeding · people requiring prevention of venous thromboembolism

It is very uncertain whether fondaparinux changes major bleeding compared with variable dose warfarin (very low certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 7 [0.37, 134.05]
1 study · 236 participants
Very low

Fondaparinux vs 1 mg warfarin

Major bleeding · people requiring prevention of venous thromboembolism

It is very uncertain whether fondaparinux changes major bleeding compared with 1 mg warfarin (very low certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 3 [0.32, 28.43]
1 study · 236 participants
Very low

Fondaparinux vs edoxaban

Major bleeding · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Very low

Fondaparinux vs mechanical thromboprophylaxis

Major bleeding · people requiring prevention of venous thromboembolism

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Low

Fondaparinux vs placebo

Major bleeding · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 2.56 [1.48, 4.44]
8 studies · 6659 participants
Moderate

Fondaparinux plus vitamin K antagonist vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).

2 findings from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.15 [0.39, 3.44]
2 studies · 2645 participants
Moderate
Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.05 [0.64, 1.71]
2 studies · 2645 participants
Moderate